Amneal Scores Second US Biosimilar Approval With Avastin Rival
Alymsys Bevacizumab With mAbxience Is Second Of Three Expected Nods This Year
Executive Summary
Amneal has received approval for its second US biosimilar in the form of the mAbxience-developed Alymsys rival to Avastin. The product represents just the third biosimilar version of bevacizumab to be approved in the US.
You may also be interested in...
Amneal Makes It Three With Pegfilgrastim Approval
Amneal has celebrated its third US biosimilar approval of 2022 with an FDA nod for its Fylnetra (pegfilgrastim-pbbk) rival to Neulasta, as the firm makes launch preparations for all three products across the second half of the year.
Viatris And Biocon Launch Bevacizumab Biosimilar In Canada
Viatris and Biocon have introduced their Abevmy biosimilar bevacizumab version of Avastin in Canada. Marking the third oncology biosimilar – and the fourth biosimilar overall – to be launched by Viatris in Canada, the product will face multiple other approved bevacizumab rivals in the market.
Amneal Sets $200m Sales Ambition For Biosimilar Trio
Amneal management has offered additional detail on the firm’s burgeoning biosimilars business, revealing a “peak” sales estimate of $200m for its current roster of three products as well as indicating plans to expand its pipeline both through licensing and internal development.